Price
$207.68+8.66%Social Signal Score
Analyst Ratings
24 analysts52-week range
- Last close
- $207.68
- Off 52w high
- -6.1%
- 200-day average
- $135.43
- vs 200-day
- +53.4%
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark A. Goldsmith
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 883
- Beta
- 1.41
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 13.78
Financials
Revenue
$0.00-100.0%Net Income
$-644.37MEBITDA
$-620.59MFree Cash Flow
$-389.61MEPS (diluted)
$-3.06Shares Outstanding (diluted)
210.89M+478.2%Operating Expenses
$505.13MCash & Debt
$3.94BReturn of Capital
$0.00Revenue by Segment (annual)
$35.38MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-1.13B | $-5.95 |
| 2024 | $0.00 | $-600.09M | $-3.58 |
| 2023 | $11.58M | $-436.37M | $-3.86 |
| 2022 | $35.38M | $-248.71M | $-3.08 |
| 2021 | $29.39M | $-187.09M | $-2.47 |
| 2020 | $42.98M | $-108.16M | $-1.62 |
| 2019 | $50.04M | $-47.66M | $-1.31 |
| 2018 | $20.16M | $-41.79M | $-1.15 |
| 2017 | $0.00 | $-31.13M | $-0.85 |
Valuation
RVMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30+50.00%Social Signal Score
Mentions (51)
- Newsglobenewswire.com·1d ago·Negative
…onrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 clinical trial evaluating the combination of RASONQUE (daraxonrasib), a …
View source ↗ - News (RSS)seekingalpha·2d ago·Neutral
Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold
View source ↗ - News (Marketaux)seekingalpha.com·2d ago·Neutral
Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold (NASDAQ:RVMD) Revolution Medicines, [+144 characters]
View source ↗ - News (RSS)forbes·7d ago·Neutral
Why The EV Charging Revolution Needs Batteries That Never Move Could space-age battery technology unlock faster EV charging? EnerVenue’s stationary storage batteries could ease grid constraints and make renewable energy more useful.
View source ↗ - News (RSS)seekingalpha·7d ago·Positive
Twist Bioscience: Don't Confuse A Short Squeeze With An AI Revolution
View source ↗ - Newsfool.com·11d ago·Neutral
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.
View source ↗ - News (RSS)zerohedge·11d ago·Neutral
Mamdani Campaign Alum Living In China Talks US Revolution: "Very Surprised If There's No Violence Going Forward" Mamdani Campaign Alum Living In China Talks US Revolution: "Very Surprised If There's No Violence Going Forward" Explicit calls to overthrow capitalism only suggest revolutionary goals within the reformist socialist movement. There have been reports that some of these reformist socialists have coordinated with foreign subversion networks in Cuba and China or used NGOs to conduct hybri
View source ↗ - News (RSS)zerohedge·15d ago·Positive
Trump Announces 'AI Force', Plans To Name AI Czar As US Pushes Tech Dominance Trump Announces 'AI Force', Plans To Name AI Czar As US Pushes Tech Dominance Authored by AG News Staff via American Greatness, President Donald Trump announced plans to form an "AI Force" and appoint an artificial intelligence czar as his administration looks to promote the rapidly growing technology while using existing laws to address potential wrongdoing. Trump argued Democrats are attempting to create public doubt
View source ↗ - News (RSS)zerohedge·17d ago·Positive
Huge Parallel Pro-Iran Demonstrations Take Over Sanaa & Tehran Huge Parallel Pro-Iran Demonstrations Take Over Sanaa & Tehran Parallel protests were held in Tehran and Sanaa on Friday - both involving Shia populations expressing defiance at the US-Saudi-Israel axis, at a moment the region is on fire and Iran and its proxies seek to assert dominance and control over global energy transit chokepoints. All the while American bases and forces are largely in retreat, as even Pentagon internal finding
View source ↗ - News (RSS)fool·17d ago·Negative
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.
View source ↗ - News (RSS)independent·18d ago·Negative
Revolution Beauty set for return to profit amid turnaround The group expects to report half-year underlying earnings of ‘not less than’ £2 million, following losses of £12.5 million a year earlier.
View source ↗ - News (RSS)standard·18d ago·Negative
Revolution Beauty set for return to profit amid turnaround The group expects to report half-year underlying earnings of ‘not less than’ £2 million, following losses of £12.5 million a year earlier.
View source ↗ - Newsfool.com·19d ago·Positive
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? Revolution Medicines validated its approach to treating certain cancers with a recent regulatory approval. The company's new medicine might become the top-prescribed treatment in its indication.
View source ↗ - 4chan /biz/biz·21d ago·Positive
>>62691401 We need a Revolution against (((tptb))) https://youtu.be/Lz4Vsd2oRuc?si Covfefe
View source ↗ - News (Marketaux)gurufocus.com·21d ago·Positive
RVMD Stock Rises on FDA Breakthrough Therapy Designation Amid High Price-to-Sales Valuation On September 14, 2026, Revolution</e[+258 characters]
View source ↗ - Newsglobenewswire.com·21d ago·Negative
…ombination with Chemotherapy for First Line Metastatic Pancreatic Cancer REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company's RAS(ON) multi-sele…
View source ↗ - News (RSS)seekingalpha·31d ago·Neutral
Vertiv: The Backbone Of AI Revolution
View source ↗ - Newsmarketbeat.com·31d ago·Neutral
Revolution Medicines Got Its Breakthrough—What Moves It Next? Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.
View source ↗ - Newszacks.com·31d ago·Neutral
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue? Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsglobenewswire.com·33d ago·Negative
…cines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib…
View source ↗ - News (Marketaux)seekingalpha.com·34d ago·Positive
Revolution Medicines: Benefit Vs Reality Compared To Peer Therapeutics (NASDAQ:RVMD) Revolution Medicines ([+191 characters]
View source ↗ - News (RSS)nyt·36d ago·Negative
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
View source ↗ - News (RSS)seekingalpha·36d ago·Positive
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions
View source ↗ - News (RSS)seekingalpha·37d ago·Neutral
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan
View source ↗ - News (RSS)thestreet·37d ago·Negative
Patients with the deadliest cancer finally have something that works The FDA just cleared a first-of-its-kind pancreatic cancer pill from Revolution Medicines.
View source ↗ - Newsseekingalpha.com·37d ago·Negative
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor targeting metastatic pancreatic cancer. RVMD's multi-selective approach addresses a broad spectrum of RAS mutations, positioning RASONQUE as a potential blockbuster with significant market opportunity. Despite a strong cash position ($3.9B), RVMD will incur substantial losses through 2028, with profitability only …
View source ↗ - Newsdefenseworld.net·38d ago·Positive
Biotech Stocks To Watch Today – August 27th Moderna, Revolution Medicines, and Amgen are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop products or technologies based on biology, such as pharmaceuticals, vaccines, medical treatments, diagnostics, and genetic therapies. For investors, these stocks can offer significant growth potential but
View source ↗ - News (RSS)yahoo·38d ago·Neutral
Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?
View source ↗ - News (RSS)yahoo·38d ago·Neutral
Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It
View source ↗ - News (Marketaux)gurufocus.com·38d ago·Positive
RVMD Maintained by UBS -- Price Target Raised to $265 On October 10, 2023, UBS maintained its [+188 characters]
View source ↗ - Newsmarketbeat.com·38d ago·Negative
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer Revolution Medicines NASDAQ: RVMD said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma.
View source ↗ - News (RSS)fool·38d ago·Positive
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? The biotech's Rasonque is already available for prescription.
View source ↗ - Newsfool.com·39d ago·Neutral
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. It's a cancer medication with immense potential. In clinical testing, the pill was shown to double the survival rate of pancreatic cancer patients.
View source ↗ - News (RSS)seekingalpha·39d ago·Positive
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
View source ↗ - Newsseekingalpha.com·39d ago·Positive
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
View source ↗ - Newszacks.com·39d ago·Neutral
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.
View source ↗ - News (Marketaux)gurufocus.com·40d ago·Neutral
Revolution Medicines (RVMD) Launches Rasonque Amid High Valuation and Mixed Insider Signals On August 26, 2026, Revolution [+307 characters]
View source ↗ - News (Marketaux)gurufocus.com·40d ago·Positive
RVMD Gains FDA Nod for Pancreatic Cancer Drug Amid High Price-to-Sales Valuation On August 26, 2026, Revolution [+319 characters]
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer This release contains multimedia assets available for download here
View source ↗ - Newsbarrons.com·40d ago·Negative
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,' has been granted approval in patients with pancreatic adenocarcinoma.
View source ↗ - Newswsj.com·40d ago·Negative
The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patients within five years.
View source ↗ - Newsreuters.com·40d ago·Negative
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
View source ↗ - News (RSS)yahoo·42d ago·Neutral
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?
View source ↗ - Newsfool.com·42d ago·Neutral
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't? Druckenmiller added roughly 26.5% to his position in Revolution Medicines in Q2. Analysts like the biotech stock, but the consensus price target reflects only modest upside potential.
View source ↗ - News (RSS)zerohedge·44d ago·Negative
President AOC's First Term President AOC's First Term Authored by Adam Sharp via DailyReckoning.com, The date is August 20th, 2032. We’re nearing the end of Alexandria Ocasio-Cortez’s first term as president. The wave of naive optimism that swept her into power has faded. But the damage is done. With a majority in both the Senate and House, the Democrats made big moves. First they eliminated the Senate filibuster. No more 60 votes needed to pass most legislation. Now a simple majority will do. T
View source ↗ - News (RSS)yahoo·46d ago·Negative
The AI-Powered Income Planning Revolution Has Arrived
View source ↗ - News (RSS)seekingalpha·47d ago·Neutral
Investing In The Building Blocks Of The Humanoid Revolution - Part 2 (The Brain)
View source ↗ - News (RSS)zerohedge·47d ago·Neutral
The DSA's War On Wealth The DSA's War On Wealth Authored by James Rickards via The Daily Reckoning, Communism is on the rise in the United States and has now entered otherwise mainstream Democratic Party politics. The Democratic Socialists of America (DSA) is on track to increase the number of its members in Congress from two to at least six in January, possibly more. That's not including Sen. Bernie Sanders, who calls himself a democratic socialist. A DSA member named Francesca Hong just came w
View source ↗ - News (RSS)investing·49d ago·Neutral
Revolution Medicines stock hits all-time high at 208.77 USD
View source ↗ - News (RSS)yahoo·52d ago·Neutral
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
View source ↗ - Newsbusinesswire.com·57d ago·Negative
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinica
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-2.40 per share
Typical surprise -15.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-3.06 vs $-2.04miss
- Wed, May 6$-2.29 vs $-1.84miss
- Wed, Feb 25$-1.86 vs $-1.58miss
- Wed, Nov 5$-1.61 vs $-1.42miss
- Wed, Aug 6$-1.31 vs $-1.14miss
- Wed, May 7$-1.13 vs $-1.12miss
Estimates and results for RVMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RVMD officers and directors.
- Bought
- —
- Sold
- $78.2m
0 trades
81 trades
- Sandler Alan B.sold
- Sandler Alan B.sold
- Sandler Alan B.sold
- Sandler Alan B.sold
- Sandler Alan B.sold
- Cislini Jeffsold
- Mancini Anthonysold
- Mancini Anthonysold
19 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RVMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.